Stock Analysis
UroGen Pharma Ltd. (URGN) Stock Analysis
UroGen Pharma Ltd. (URGN) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
UroGen Pharma Ltd. (URGN) currently has an AIQ Score of 53/100, indicating a neutral setup. Quality is the strongest factor at 68/100. Risk is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
URGN at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $26.18 |
| AIQ Score | 53/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $1.32B |
| P/E Ratio (TTM) | -19.83 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.03 |
| Revenue (Q3 FY2026) | $89M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.33 |
| Volume | 700.02K |
| 52-week range | $16.50-$50.81 |
| RSI 14 | 28.74 |
| 50-Day SMA | $37.00 |
| 200-Day SMA | $31.69 |
| Analyst Price Target | $58.00 |
| Next Earnings | Mar 1, 2027 |
URGNUroGen Pharma Ltd.
Healthcare / Biotechnology
Low Priority
In Line With Peers
Latest quote
- Momentum40
- Value64
- Quality68
- Risk resilience40
- Sentiment—
URGN Stock Analysis Summary
UroGen Pharma Ltd. (URGN) currently has an AIQ Score of 53/100, indicating a neutral setup. Quality is the strongest factor at 68/100. Risk resilience is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, URGN has AIQ Score of 53/100 with Quality base of 68/100 and fading Risk resilience at 40/100. Wait for component alignment before adding exposure.
Quality (68/100) leads while Risk resilience (40/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.80% stock move · URGN classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is URGN Bullish or Bearish Right Now?
URGN currently has a neutral overall setup. Quality is the strongest factor at 68/100, while Momentum is weakest at 40/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 68/100.
- - Analyst target implies +121.54% upside from the latest quote.
- - Momentum is weak at 40/100.
- - Risk Resilience is weak at 40/100.
- - Price is -17.38% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (36 vs 6).
Current Consensus
URGN's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 4 neutral, and 36 sell votes. URGN's 14-day RSI is 28.74, which places the stock in an oversold momentum range. URGN's beta is 1.33, indicating greater market sensitivity than the broad market.
What Changed in URGN?
The largest recent change in URGN is Momentum moving down by 12.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the URGN Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
URGN Decision Framework
Public evidence layers, setup checks, and risk context for UroGen Pharma Ltd..
UroGen Pharma Ltd. (URGN) Stock Analysis
UroGen Pharma Ltd. has an AIQ Score of 53/100 in a Neutral regime. Quality is strongest at 68/100. Beta is 1.33, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | URGN is in a Neutral AIQ regime with score 53/100. |
| Signal Conflict | The primary conflict is that quality leads at 68/100 while momentum lags at 40/100. |
| Factor Evidence | Momentum 40/100 · Value 64/100 · Quality 68/100 · Risk 40/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 68/100.
Momentum is 40/100 and RSI (14) is 28.7.
URGN is in a Neutral regime at 53/100.
Risk factor is 40/100 with beta 1.33 and annual volatility 61.94%.
Current conflict: quality leads at 68/100 while momentum lags at 40/100.
URGN Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
URGN Fundamentals
URGN valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
URGN Technical Analysis
URGN technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
URGN Stock Catalysts
Track URGN earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
URGN Dividend Analysis
URGN dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
URGN Financial Data
URGN revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
URGN Risk Analysis
URGN volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
URGN Stock News
URGN stock news, market tone, recent headlines, and catalyst context.
URGN vs Biotechnology Peers
Current peer cohort: URGN · UTHR · VCEL · VKTX · VOR. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| URGN Current stock | 53/100 | 64/100 | 40/100 | 40/100 | 0.39 | 61.94% | Current |
| UTHR United Therapeutics Corporation | 76/100 | 78/100 | 68/100 | 83/100 | 0.76 | 35.02% | URGN vs UTHR |
| VCEL Vericel Corporation | 77/100 | 65/100 | 90/100 | 64/100 | 0.93 | 45.04% | URGN vs VCEL |
| VKTX Viking Therapeutics, Inc. | 41/100 | — | 47/100 | 41/100 | -0.15 | 69.18% | URGN vs VKTX |
| VOR Vor Biopharma Inc. | 66/100 | — | 72/100 | 46/100 | 1.15 | 93.53% | URGN vs VOR |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for URGN: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching URGN
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for URGN
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
URGN Stock FAQ
What is URGN stock price today?
UroGen Pharma Ltd.'s current stock price is $26.18. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is URGN bullish or bearish right now?
URGN's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is URGN's market cap?
URGN's market cap is $1.32B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is URGN's current P/E ratio?
URGN's current P/E ratio is -19.83 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is URGN's RSI?
URGN's 14-day RSI is 28.74 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is URGN above its 50-day and 200-day moving averages?
URGN is -29.25% from its 50-day SMA and -17.38% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is URGN's next earnings date?
URGN's next earnings date is currently listed as Mar 1, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does URGN pay a dividend?
URGN's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.